Mobile

An open-label, multi-center, 24-month extension study to evaluate the safety of ranibizumab as symptomatic treatment for visual impairment due to diabetic macular edema in patients who have completed ...

Update Il y a 4 ans
Reference: EUCTR2008-007467-17

An open-label, multi-center, 24-month extension study to evaluate the safety of ranibizumab as symptomatic treatment for visual impairment due to diabetic macular edema in patients who have completed the RESTORE trial

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective of this trial is to evaluate the ocular and non-ocular adverse events during the 24-months study period in patients treated with Lucentis (0.5 mg)

Inclusion criteria

  • Diabetic Macular Edema (DME)

Links